ADA 2026: The Multi-Agonist and Oral Incretin Readouts, Summarized
ADA 2026 delivered phase 3 data on a triple GLP-1/GIP/glucagon agonist, a dual agonist, CagriSema and two oral agents. Here is the map.
Tagged
incretin
1 note in this topic
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.